A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib

by Yuki Matsumura, Sho Inomata, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Masayuki Watanabe, Yuki Ozaki, Takumi Yamaura, Mitsuro Fukuhara, Satoshi Muto, Naoyuki Okabe, Takeo Hasegawa, Yutaka Shio, Hiroyuki Suzuki
Published 2021-08-01